Lilly Partners with Innovent for Abemaciclib Commercialization in China Amid Surging Market Cap and Strategic Expansion

Text: Yaoshida

On June 30, Eli Lilly and Innovent officially announced a commercialization partnership, whereby Innovent secured the exclusive rights to import, market, and promote Verzenio® (abemaciclib tablets), a targeted therapy for breast cancer, in mainland China. Eli Lilly will retain responsibility for manufacturing supply and ongoing research and development of the drug.

The product covers all indications across early and late stages and is included in the national medical insurance. This collaboration marks the eighth strategic partnership between the two parties, expanding the portfolio to seven products, leveraging Innovent’s established oncology distribution channels to enhance the accessibility of innovative breast cancer therapies in China.

On June 26 (U.S. Eastern Time), Eli Lilly’s stock price surged 7.13%, closing at $1,208.12 and hitting an all-time high intraday. Its total market capitalization exceeded $1.14 trillion, firmly maintaining its position as the world’s most valuable pharmaceutical company.

This round of gains was driven by multiple positive catalysts, including the European Union’s positive review opinion for the BTK inhibitor Jaypirca, the implementation of Medicare’s GLP-1 insurance subsidy policy in the United States in July, and investment banks’ upward revisions of target prices;

The company’s core GLP-1 tirzepatide series generated over $12.8 billion in revenue in the first quarter, driving an upward revision of the full-year revenue guidance to $82–85 billion thanks to a diversified pipeline; however, current valuations remain elevated, with risks persisting from competitors and drug pricing policies.

Looking back to June 24, Eli Lilly and Abbisko Therapeutics upgraded their global strategic R&D collaboration. The two parties will conduct early-stage new drug development around multi-disease targets, with the total potential value of the cooperation reaching up to $1.9 billion, including upfront payments, development and commercialization milestones, and tiered sales royalties.

Lilly Asia Ventures invested in HeYu in its early years, and the two parties engaged in small-scale target collaboration in 2022.

In 2026, Eli Lilly also successively reached multi-billion-dollar BD deals with Haisco and Insilico Medicine, continuing to tap into innovative small-molecule R&D resources in China.

Overall, Eli Lilly is achieving strong performance and market capitalization driven by its GLP-1 products, while simultaneously pursuing a dual-pronged strategy in China. By partnering with Innovent to bolster its commercialization channels for mature oncology drugs and collaborating with local biotech firms such as Allist to secure early-stage innovative pipelines, the company continues to refine its comprehensive, end-to-end layout in the Chinese market.

Welcome to the public course held in Jinan on July 4-5

Disclaimer: The content of this official account is intended to provide industry updates for professionals in the pharmaceutical and healthcare sectors. It does not constitute any medical, medication, purchasing, or investment advice. The content does not guarantee completeness or accuracy. Your access to this content does not imply that you are a specific intended reader of this official account. Please read with caution.

Follow the official account to access reliable, professional news and analytical content.